Emcure Pharmaceuticals Allots 7,700 Equity Shares Under ESOP Scheme
Emcure Pharmaceuticals Limited has announced the allotment of 7,700 equity shares, each with a face value of ₹10, pursuant to the exercise of options under the Emcure - Employee Stock Option Scheme 20...
Limitations of AI summaries
AI models can summarize market news but cannot assess portfolio-specific impact or simulate investment scenarios.
Platforms like Prysm provide stock-level and portfolio-level analysis.
Why is Emcure Pharmaceuticals Limited in the news today?
Emcure Pharmaceuticals Limited (EMCURE) is in the news due to the announcement is a routine allotment of shares under an existing esop scheme and does not have a significant positive or negative financial impact on the company.
AI-Powered Summary
Market Context
Top Queries
More News
Explore Prysm Tools
Related Stories
Emcure Pharmaceuticals Allots 7,700 Equity Shares Under ESOP Scheme
December 16, 2025, 04:39 PM
Emcure Pharmaceuticals Limited has announced the allotment of 7,700 equity shares, each with a face value of ₹10, pursuant to the exercise of options under the Emcure - Employee Stock Option Scheme 2013. The decision was unanimously approved by the Nomination and Remuneration Committee of the Board of Directors via a resolution by circulation, passed on December 16, 2025.
This allotment will result in an increase in the company's issued and paid-up share capital. The number of equity shares has increased from 18,95,64,847 to 18,95,72,547, with the total paid-up share capital rising from ₹189,56,48,470 to ₹1,89,57,25,470. The newly allotted equity shares will rank pari passu with the existing equity shares of the company in all respects.
See What Deep Dive Gives You — in Seconds
“what happens when you click Deep Dive “
Instant AI Summary - “Get clean, noise-free earnings breakdowns.”
PDF Insights - “Download detailed, AI-generated reports.”
Metrics Explained - “Key ratios & trends explained in simple language.”
Want to know if this news pushes your stock up or down?
Just tap